Particle.news

Download on the App Store

Anti-CD30 therapy restores PD-1 immunotherapy efficacy in resistant skin cancers

Adding an anti-CD30 agent to PD-1 blockade shows a significant survival boost in patients with refractory metastatic melanoma.

Image

Overview

  • Researchers at Newcastle University discovered that combining anti-CD30 therapy with anti-PD1 immune checkpoint blockade reverses resistance by targeting CD30+ regulatory T cells.
  • A mouse model with PD-1 deficiency confined to regulatory T cells showed that PD-1 blockade elevates CD30 expression and boosts Treg immunosuppression.
  • A US Phase II trial of anti-PD1 antibodies plus Brentuximab Vedotin produced a 24% median survival advantage in patients with refractory metastatic cutaneous melanoma.
  • More than 60% of cancer patients fail to respond to ICB monotherapy, highlighting the urgency for alternative treatment strategies.
  • Scientists believe the combination approach could also benefit patients with other solid tumors such as lung, bowel and pancreatic cancers.